Shire Pharmaceuticals Group Plc
Basingstoke, England (ots/PRNewswire) - - New Data Show FOSRENOL Is an Effective Monotherapy - Leading to Improved Phosphate Reduction in Dialysis Patients Previously Receiving Alternative Phosphate Binder Therapies New data show calcium-free FOSRENOL (lanthanum carbonate) further reduces phosphate levels in dialysis patients previously receiving other ...
Toronto (ots/PRNewswire) - Medify Solutions Limited today announces its own in-house product for roll out to the NHS. This new capability will replace the legacy generic solution provided for Medify by Pervasic and specifically focuses on the known requirements of Healthcare professionals and the global delivery of MedifyRemote. The development has been led ...
Lund, Sweden (ots/PRNewswire) - - New Patient Data in COPD Brings Valuable Insight to the Consequences of Exacerbations on Patients' Lives, Demonstrating a Strong Psychological Impairment New data from a multinational, interview-based patient study, published today in the medical journal CHEST, shed light ...
Macclesfield, England (ots/PRNewswire) - - Thousands More Women Will Have the Opportunity to Take 'Arimidex' as Part of Their Breast Cancer Treatment and Improve Their Chances of Living Longer, Cancer Free - For Health Professional and Consumer Press - For International Journalists - Not for US ...
Bangalore, India (ots/PRNewswire) - - Company's First Integrated Development Center (IDC) Opens in Bangalore as Part of Strategic Development of its Global Clinical Studies Program GE Healthcare, a division of the General Electric Company (NYSE:GE) today announced the opening of its first ...
Paris (ots/PRNewswire) - Bristol-Myers Squibb announced today that the European Commission has granted an approval for BARACLUDE(R) (entecavir) for the treatment of chronic hepatitis B virus infection. BARACLUDE(R) is an oral antiviral therapy specifically designed to block the replication of hepatitis B ...
Birmingham, England (ots/PRNewswire) - For Non-US Journalists Only - For Severe COPD Patients Treated With Budesonide Added to Either Formoterol (Symbicort, AstraZeneca) and/or a Short Acting Bronchodilator, There is a Reduced Risk of Mortality Compared to Patients Treated With Only Formoterol and/or ...
bioLytical(TM) Laboratories (Inc.)
Richmond, Canada (ots/PRNewswire) - bioLytical(TM) Laboratories announced today, that their INSTI(TM) kit, a rapid HIV antibody test developed by the company, received CE Mark approval in their European Community. "We are delighted to have received CE Mark approval for INSTI," says Robert Mackie, President and CEO. "To have CE Mark approval will now allow us to ...
Amsterdam (ots/PRNewswire) - Data presented at the 2006 European League Against Rheumatism (EULAR) Annual Congress in Amsterdam show that 3 years of treatment with the selective co-stimulation modulator abatacept, maintains improvements in Rheumatoid Arthritis (RA) symptoms, physical function, disease activity ...
Amsterdam (ots/PRNewswire) - New data presented at the 2006 European League Against Rheumatism (EULAR) Annual Congress from the one-year open label extension of the 6-month ATTAIN trial (Abatacept Trial in Treatment of Anti-TNF INadequate responders)[1] in which all patients were treated with abatacept, a ...
Basel, Switzerland (ots/PRNewswire) - The US approval of TMC114 (darunavir), a new boosted protease inhibitor (PI), provides the opportunity to build a potent new treatment combination with the fusion inhibitor FUZEON (enfuvirtide) that can successfully combat the HIV virus in treatment resistant patients. ...
Basel, Switzerland and Amsterdam (ots/PRNewswire) - - First RA Drug to Achieve These Results in Patients With an Inadequate Response to Currently Available Treatments New data presented at the EULAR meeting (European League Against Rheumatism) show for the first time that MabThera (rituximab), a unique B cell targeted therapy, is able to significantly ...
- Further Information can bo downloaded at 18.00 hrs on: http://www.presseportal.ch/de/story.htx?firmaid=100010455&lang=2 - Basel (ots) - The metropolitan areas of Western Europe benefited disproportionately from the dot.com boom in the second ...
The European Science Foundation (ESF)
Brussels (ots/PRNewswire) - - Europe's Experts in the Field Will Hear the Plan and Discuss the Recommendations at Their Annual Meeting in Amsterdam this Week. The world's largest meeting of experts in rheumatic diseases will today hear and debate calls for a pan-European approach to prioritise and combine ...
Basel, Switzerland (ots/PRNewswire) - - Newest HIV Drug Works Better in Combination With FUZEON(R) The emergence of new HIV treatments, such as boosted protease inhibitors (PI), has led to a change in treatment goals for people living with drug-resistant HIV. Up until recently, it has been reluctantly ...
Shire Pharmaceuticals Group Plc
Basingstoke, England (ots/PRNewswire) - - First Human Cell Line-Derived Erythropoietin Research Reported BASINGSTOKE, England, June 16 /PRNewswire/ -- - Abstract Numbers: 562 and 576 Effective treatment of anaemia in patients suffering from chronic kidney disease (CKD)(x) is possible with the first erythropoietin product produced in a human cell ...
Mental Health Research Institute and Monash University of Victoria, Australia
Victoria, Australia (ots/PRNewswire) - A new study published by physicians from the Mental Health Research Institute and Monash University of Victoria, Australia, showed that all atypical antipsychotics studied were equally efficacious when used at optimal doses as primary medication for inpatients with acute ...
Spanish Society of Hypertension
Madrid, Spain (ots/PRNewswire) - - Caduet, Single-Pill Amlodipine and Atorvastatin Combination, Helps Patients Reduce Calculated Risk for a Fatal CV Event by 29 to 52 Percent Results from the JEWEL programme show that single-pill amlodipine/atorvastatin therapy, also known as Caduet, is an effective ...
Research Triangle Park, North Carolina (ots/PRNewswire) - - Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year Quintiles Transnational Corp. today announced that its Quintiles East Asia subsidiary has been named the Asia Pacific region's Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year by the consulting firm Frost ...
Toronto, Canada (ots/PRNewswire) - - The Increase of OPG Expression Explains the Uncoupling Effect of Protelos(R) on Bone Metabolism Exciting new data presented at the World Congress on Osteoporosis further the understanding of the unique dual mode of action of the anti-osteoporotic agent Protelos(R) ...
Leeds, England (ots/PRNewswire) - - Significant Response Rates and Manageable Side Effects Also Exhibited In Poor-Prognosis and Difficult-to-Treat Patients According to interim data from a new international Phase III study called CAM 307, previously untreated patients with progressive B-cell chronic ...
Basel, Switzerland (ots/PRNewswire) - A new study(1) suggests that treatment with the combination of the innovative cancer drugs Avastin (bevacizumab) and Tarceva (erlotinib) or Avastin with chemotherapy, improves progression-free survival in patients with recurrent or refractory non-small cell lung cancer ...
Atlanta, Georgia (ots/PRNewswire) - - 86% Rate of Tumour Control in myxoid liposarcomas - Correlation Between DNA Repair Gene Expression and Response Rate in Sarcomas - 78% Rate of Tumour Control in Platinum Pretreated Ovarian Cancer Patients PharmaMar highlights the results of three important studies out of 10 presented on Yondelis(R) at the Annual ...
Atlanta (ots/PRNewswire) - - Enrolment to a Pivotal Phase III Study of ZD6474 in Advanced Non-Small Cell Lung Cancer (NSCLC) is Also Underway AstraZeneca today announced at the annual meeting of the American Society of Clinical Oncology (ASCO) further results of two key Phase II studies of the novel ...
Basel, Switzerland (ots/PRNewswire) - - Real World Practice Confirms Avastin's Efficacy and Safety in Advanced Colorectal Cancer New data from 4,000 patients show that Avastin (bevacizumab rhuMAb-VEGF) enables patients with advanced colorectal cancer (CRC) to live longer without progression of their ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases. ISA247 is a novel calcineurin ...
Toronto (ots/PRNewswire) - - For Healthcare and Medical Reporters (non-US and non-UK) The results of a pivotal study confirm the potential of quetiapine fumarate (SEROQUEL) as a monotherapy (treatment with a single antipsychotic medicine) for acute bipolar depression. Quetiapine is an atypical ...
Ingelheim, Germany (ots/PRNewswire) - - Not for Distribution or Publication in the United States New omnibus data from the largest global survey due to be published, conducted on the epidemiology of constipation, were presented today at the Digestive Disease Week congress in Los Angeles. The survey, sponsored by Boehringer Ingelheim, offers new insights into the incidence of constipation and shows that ...
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Professional and Consumer Journalists - Not for Distribution to USA Media - Survey Shows 25% of World's Population Suffer From Common and Distressing Ailment That can be Effectively Treated New data presented at the premier international gastroenterology congress Digestive Disease Week (DDW) 2006 ...
San Diego, California (ots/PRNewswire) - - For Accredited International Healthcare Journalists Only - Management of Exacerbations `Crucial' to Reduce COPD Mortality Survey results from the `Time to Live' report, presented today at the American Thoracic Society International Congress, show over two thirds of primary care physicians (66%) fear COPD will be ...